Cargando…

Effects of intensive insulin therapy combined with low molecular weight heparin anticoagulant therapy on severe pancreatitis

The current study explored the effects of intensive insulin therapy (IIT) combined with low molecular weight heparin (LMWH) anticoagulant therapy on severe acute pancreatitis (SAP). A total of 134 patients with SAP that received treatment between June 2008 and June 2012 were divided randomly into gr...

Descripción completa

Detalles Bibliográficos
Autores principales:	DU, JUN-DONG, ZHENG, XI, HUANG, ZHI-QIANG, CAI, SHOU-WANG, TAN, JING-WANG, LI, ZHAN-LIANG, YAO, YONG-MING, JIAO, HUA-BO, YIN, HUI-NAN, ZHU, ZI-MAN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2014
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061186/ https://www.ncbi.nlm.nih.gov/pubmed/24944612 http://dx.doi.org/10.3892/etm.2014.1694

Ejemplares similares

Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care
por: Doidge, James C., et al.
Publicado: (2023)

Low-molecular weight heparin infusion as anticoagulation for haemodialysis
por: Wong, Steve Siu-Man, et al.
Publicado: (2016)

A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin
por: Tao, Ende, et al.
Publicado: (2020)

Heparin algorithm for anticoagulation during continuous renal replacement therapy
por: Ostermann, Marlies, et al.
Publicado: (2010)

Non-Anticoagulant Activities of Low Molecular Weight Heparins—A Review
por: Feng, Ke, et al.
Publicado: (2023)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

Heparin vs recombinant hirudin for anticoagulation in continuous renal replacement therapy
por: Vargas Hein, O, et al.
Publicado: (2000)

Clinical review: Anticoagulation for continuous renal replacement therapy - heparin or citrate?
por: Oudemans-van Straaten, Heleen M, et al.
Publicado: (2011)

Revised algorithm for heparin anticoagulation during continuous renal replacement therapy
por: Dickie, Helen, et al.
Publicado: (2015)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Thrombocytopenia Due to Direct Oral Anticoagulation and Low-Molecular-Weight Heparin
por: Tucker, Madeline, et al.
Publicado: (2021)

Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children
por: Raymakers-Janssen, Paulien A. M. A., et al.
Publicado: (2017)

Patients’ Plasma Activity of Heparin, low-Molecular-Weight Heparin or no Anticoagulants on Urine Based DOAC Test Strips
por: Harenberg, Job, et al.
Publicado: (2022)

Heparin or nonheparin anticoagulants for VITT
por: Arnold, Donald M.
Publicado: (2022)

Intense light as anticoagulant therapy in humans
por: Oyama, Yoshimasa, et al.
Publicado: (2020)

Heparin and Insulin for Hypertriglyceridemia-Induced Pancreatitis: Case Report
por: Jain, Deepika, et al.
Publicado: (2009)

Bilateral iliopsoas intramuscular bleeding following anticoagulant therapy with heparin: a case report
por: Murena, Luigi, et al.
Publicado: (2009)

Anticoagulation during continuous renal replacement therapy with lepirudin in patients with heparin-induced thrombocytopenia
por: Schroeder, T, et al.
Publicado: (2005)

Therapeutic Anticoagulation with Argatroban and Heparins Reduces Granulocyte Migration: Possible Impact on ECLS-Therapy?
por: Bredthauer, Andre, et al.
Publicado: (2020)

How to assess hypercoagulability in heparin-induced thrombocytopenia? Biomarkers of potential value to support therapeutic intensity of non-heparin anticoagulation
por: Barocas, Antoine, et al.
Publicado: (2023)

Not Just Anticoagulation—New and Old Applications of Heparin
por: Zang, Lixuan, et al.
Publicado: (2022)

Engineered heparins as new anticoagulant drugs
por: Vaidyanathan, Deepika, et al.
Publicado: (2016)

Non-Anticoagulant Heparins as Heparanase Inhibitors
por: Cassinelli, Giuseppe, et al.
Publicado: (2020)

Regional Citrate Anticoagulation or Heparin Anticoagulation for Renal Replacement Therapy in Patients With Liver Failure: A Systematic Review and Meta-Analysis
por: Qi, Wenqian, et al.
Publicado: (2023)

Elevated Transient Receptor Potential Melastatin 8 (TRPM8) Expression Is Correlated with Poor Prognosis in Pancreatic Cancer
por: Du, Jun-dong, et al.
Publicado: (2018)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Living kidney transplantation without perioperative anticoagulation therapy for a patient with heparin‐induced thrombocytopenia
por: Nishida, Hayato, et al.
Publicado: (2020)

Hypertriglyceridemic pancreatitis managed with heparin and insulin: a case report
por: Anbessie, Zablon Mesfin, et al.
Publicado: (2023)

Management of Bivalirudin Anticoagulation Therapy for Extracorporeal Membrane Oxygenation in Heparin-Induced Thrombocytopenia: A Case Report and a Systematic Review
por: Zhong, Han, et al.
Publicado: (2020)

Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation
por: Andrade, S.A., et al.
Publicado: (2012)

Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden
por: Lund, Lars Christian, et al.
Publicado: (2022)

Gigantic retroperitoneal hematoma as a complication of anticoagulation therapy with heparin in therapeutic doses: a case report
por: Daliakopoulos, Stavros I, et al.
Publicado: (2008)

Use of activated clotting time to monitor anticoagulation in patients receiving unfractionated heparin on renal replacement therapy
por: Bidwai, A, et al.
Publicado: (2011)

Monitoring Anticoagulation with Unfractionated Heparin on Renal Replacement Therapy. Which is the Best aPTT Sampling Site?
por: Anton, Florin Ioan, et al.
Publicado: (2020)

Decreased mortality among hospitalized coronavirus disease 2019 patients who underwent anticoagulant therapy with heparin
por: Yethindra, Vityala, et al.
Publicado: (2020)

Superiority of bivalirudin over heparin anticoagulation therapy for extracorporeal membrane oxygenation? Too early to draw conclusions
por: Gu, Jie, et al.
Publicado: (2023)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1d6ds1i50aqtlku4tknbqq02hb